Blog Big Molecule Watch September 18, 2018

Boehringer Ingelheim Announces Positive Phase III Results for Its Adalimumab Biosimilar

On September 12, 2018, Boehringer Ingelheim announced positive results from a Phase III clinical trial for its approved adalimumab biosimilar, Cyltezo®. The clinical trial compared the efficacy, safety and immunogenicity of Cyltezo® and Humira® in patients with moderate-to-severe chronic plaque psoriasis.  According to Boehringer Ingelheim, the study confirmed equivalence of Cyltezo® and Humira®, finding no clinically meaningful differences in efficacy, safety and immunogenicity between the two drugs.

The post Boehringer Ingelheim Announces Positive Phase III Results for Its Adalimumab Biosimilar appeared first on Big Molecule Watch.